The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Taking into account the substantial doubts concerning the potential benefit of postoperative
part in the perioperative chemotherapy regimen we designed a study assessing value of this
approach in gastric cancer. To improve compliance with a protocol regimen of this aggressive
combined therapy we replaced tested in the MAGIC trial ECF regimen with more effective and
better tolerable EOX chemotherapy regimen. The value of postoperative three-cycle EOX regimen
will be tested in patients with locoregionally advanced gastric cancer with positive
pathological response to preoperative three-cycle EOX chemotherapy regimen. The patients will
be randomized to the postoperative chemotherapy or to the follow-up arm.